Executive Order on Psychedelic Medicine: Unprecedented Federal Funding and Policy Alignment for Physicians, Practices, and Research Organizations

Executive Summary

President Trump signed Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness" (91 Fed. Reg. 21,709), on April 18, 2026, establishing the most comprehensive federal policy framework to date for advancing psychedelic-assisted therapies. For physicians, medical practices, and research organizations, this executive order represents an unprecedented convergence of federal funding, regulatory acceleration, and policy alignment that creates immediate opportunities for participation in what is rapidly becoming a new therapeutic frontier.

The order directs more than $139 million in federal funding through Advanced Research Projects Agency for Health (ARPA-H), creates expedited FDA review pathways that compress approval timelines from years to months, establishes Right to Try access for eligible patients, and mandates interagency collaboration across HHS, FDA, VA, and DEA. Combined with FDA's finalized clinical investigation guidance (July 14, 2026), HRSA workforce development signals, and substantial private sector investment (including Eli Lilly's $3.8 billion acquisition of AtaiBeckley), the window of opportunity for early movers is significant and time-limited.

What the Executive Order Does: Five Key Pillars

1. FDA Review Prioritization – Commissioner's National Priority Vouchers

The order directs FDA to issue Commissioner's National Priority Vouchers (CNPVs) for psychedelic drugs with Breakthrough Therapy designation, reducing review timelines from 10–12 months to just 1–2 months for qualifying products aligned with critical U.S. national health priorities.

On April 24, 2026, FDA issued CNPVs to three companies studying psilocybin for treatment-resistant depression and major depressive disorder and methylone for PTSD. FDA also permitted a Phase 1 clinical study of noribogaine hydrochloride (an ibogaine derivative for alcohol use disorder) to proceed following IND submission.

2. Right to Try Access for Psychedelic Compounds

The order directs FDA and DEA to establish a pathway for eligible patients to access investigational psychedelic drugs – including ibogaine compounds – under the Right to Try Act (21 U.S.C. § 360bbb-0a). Critically, this includes "any necessary Schedule I handling authorizations for treating physicians and researchers" consistent with 21 U.S.C. § 823 and applicable CSA waiver authority.

Right to Try eligibility requires: (1) diagnosis of a life-threatening disease or condition; (2) exhaustion of approved treatment options; and (3) inability to participate in a clinical trial.

3. ARPA-H Federal-State Funding ($50 Million+)

The order directs HHS, through ARPA-H, to allocate at least $50 million from existing funds to support and partner with state governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses. This includes federal funding, technical assistance, and data sharing.

The $50 million is structured as match funding for state government investments – states must have enacted or be developing psychedelic research legislation to qualify. Texas is the leading example, with an estimated $50–$100 million allocated for ibogaine research.

4. Interagency and Private Sector Collaboration

HHS, FDA, and the VA are directed to coordinate with private-sector entities to increase clinical trial participation, data sharing, and real-world evidence generation. Priority is given to drugs with Breakthrough Therapy designation. Data-sharing agreements will help FDA evaluate and approve psychedelic therapies more efficiently.

The VA currently has approximately 30 studies at VA sites covering PTSD, alcohol use disorder, and depression in spinal cord injury, with innovative protocols pairing psychedelics with cognitive processing therapy, massed prolonged exposure, dose optimization, and active controls.

5. Expedited Rescheduling Upon Phase 3 Completion

The Attorney General is directed to initiate scheduling review upon successful Phase 3 completion – rather than waiting for FDA approval – so that rescheduling can proceed quickly upon marketing authorization. This represents a significant acceleration over the typical rescheduling timeline.

Key Funding Sources and How to Access Them

ARPA-H EVIDENT Initiative – Up to $139.4 Million

The ARPA-H Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative is the primary federal funding vehicle, with up to $139.4 million available (including the $50 million directed by the executive order). The first research team awardees were announced April 21, 2026.

What ARPA-H seeks: Multimodal, longitudinal data collected in registered clinical trials testing rapid-acting interventions for behavioral health – including neuroplastogens (psychedelics), neuromodulation, and digital therapeutics.

How to access: Awards are made on a rolling basis. Organizations should monitor the ARPA-H EVIDENT page and open funding opportunity announcements. ARPA-H was specifically chosen for its nimble, flexible approach to funding compared to traditional NIH mechanisms.

State-Level Matching Programs ($50 Million Federal Match)

The executive order's $50 million is structured as match funding for state investments. Organizations best positioned to access these funds are those in states with existing or developing psychedelic research legislation.

• Action step: Research organizations in states with psychedelic research legislation should engage their state health agencies about partnership opportunities and positioning as research partners for state-federal matching programs.
   
• Leading example: Texas has allocated an estimated $50–$100 million for ibogaine research – the largest state-level psychedelic research investment in U.S. history.

VA Collaboration Opportunities

The VA has approximately 30 active psychedelic studies and is directed to expand collaboration with external researchers. Physicians and practices affiliated with the VA system, or institutions with VA research partnerships, may have opportunities to participate as study sites or investigators.

Private Sector and Industry-Sponsored Trials

The order encourages pharmaceutical and biotechnology company collaboration, and the market is responding. Eli Lilly's $3.8 billion acquisition of AtaiBeckley (mebufotenin, MDMA, and DMT programs), announced the same week as FDA's finalized guidance in July 2026, signals substantial industry investment. Clinical trial sites and research organizations should anticipate a significant increase in industry-sponsored trial opportunities.

HRSA Training and Workforce Development

HRSA has issued a Request for Information on training and care delivery models for administering psychedelic therapies in outpatient settings, including health centers and rural clinics (comments are due August 13, 2026). This signals potential future federal funding for workforce development programs – organizations that submitted comments will be well-positioned when funding materializes.

FDA Breakthrough Therapy Designation Benefits

While not a funding source per se, Breakthrough Therapy designation provides sponsors with intensive FDA guidance, organizational commitment, rolling review, and now CNPV eligibility. Physicians and practices involved in clinical trials should understand how BTD status benefits their research programs and positions products for the accelerated review pathway.

What This Means for Physicians and Medical Practices

• Right to Try Authorizations. The pathway for Schedule I handling authorizations for treating physicians is being developed. Physicians treating patients with life-threatening conditions who have exhausted other options may soon be able to prescribe investigational psychedelics outside of clinical trials.
   
• DEA Registration Requirements. Physicians participating in psychedelic research require individual Schedule I DEA registration (21 C.F.R. § 1301.18). Research institutions must also ensure that the facility where psychedelic research is conducted holds or obtains its own separate DEA Schedule I research registration, independent of each individual investigator's registration. The institution must maintain required Schedule I security, recordkeeping, and storage controls and be prepared for potential DEA inspection. Begin the application process now if you anticipate involvement in clinical trials.
   
• Informed Consent Obligations. FDA's finalized guidance requires that informed consent describe prolonged perception and cognition changes, increased vulnerability and suggestibility, and cardiac risks for certain compounds. Consent processes must be comprehensive and well-documented.
   
• Patient Inquiry Preparedness. Expect increased patient inquiries about psychedelic treatments as media coverage intensifies. Practices should develop standardized responses and referral pathways.
   
• Credentialing and Privileging. Hospitals and health systems will need to address credentialing standards for physicians administering psychedelic therapies. Engage your medical staff office and credentialing committees early.

What This Means for Research Organizations

• New Federal Funding via ARPA-H. The EVIDENT initiative ($139.4M) represents the largest federal investment in psychedelic research to date. Monitor rolling award opportunities and prepare competitive proposals emphasizing multimodal data collection and rapid-acting interventions.
   
• State Partnership Opportunities. Engage state health agencies in states with psychedelic research legislation to position your institution as a research partner for state-federal matching programs.
   
• VA Collaboration. Institutions with existing VA affiliations or research partnerships should explore expanded collaboration under the interagency mandate.
   
• Industry-Sponsored Trial Sites. As pharmaceutical investment grows (illustrated by Eli Lilly/AtaiBeckley), research organizations should build clinical trial site capabilities and investigator networks to capture industry-sponsored opportunities.
   
• IRB Protocol Development. FDA's finalized guidance (July 14, 2026) provides the definitive roadmap for psychedelic clinical trial design. IRBs should begin developing review frameworks, consent templates, and safety monitoring standards specific to psychedelic investigations.
   
• ARPA-H EVIDENT Monitoring. Awards are made on a rolling basis. Designate a team to actively monitor ARPA-H announcements and prepare applications for future funding cycles.
   
• Workforce Development. HRSA's RFI signals potential training grants. Institutions with psychotherapy training programs should prepare workforce development proposals for anticipated funding opportunities.

Recommended Next Steps

For Physicians:

1. Evaluate Right to Try eligibility for current patients with life-threatening psychiatric conditions who have exhausted approved treatments.
    
2. Initiate DEA Schedule I registration if you anticipate involvement in psychedelic research or Right to Try administration.
    
3. Develop patient communication protocols for responding to inquiries about psychedelic-assisted therapy availability.

For Medical Practices:

4. Review credentialing and privileging frameworks to identify how psychedelic therapy administration will be incorporated.
    
5. Assess facility requirements for multihour dosing sessions, including physical space, emergency response capabilities, and Schedule I security.
    
6. Update informed consent templates and risk management protocols to address novel psychedelic therapy risks, including cardiac monitoring for ibogaine.

For Research Organizations:

7. Monitor ARPA-H EVIDENT funding announcements and prepare competitive proposals emphasizing multimodal longitudinal data from registered clinical trials.
    
8. Engage state health agencies in states with psychedelic research legislation to position for federal-state matching opportunities.
    
9. Build clinical trial site infrastructure to capture the anticipated increase in industry-sponsored psychedelic trials.
    
10. Attend the September 14, 2026, FDA/HHS public hearing on therapeutic use of psychedelics to track regulatory direction and submit institutional perspectives.

For More Information

If you have questions about the executive order, psychedelic therapy research opportunities, ARPA-H funding, Right to Try eligibility, DEA registration, or compliance considerations, please contact Lisa Gora.

The author acknowledges with appreciation the assistance and research from Baker Donelson Summer Associate Elliott Liebling.